Copertina

Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Mariko Maxwell, Yanhong Deng, Bonnie Chen, Marina G. Silveira, James L. Boyer, David N. Assis
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
di: Ellen Werner, et al.
Pubblicazione: (2026)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
di: Leyu Zhou, et al.
Pubblicazione: (2024)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
di: Jörn M. Schattenberg, et al.
Pubblicazione: (2026)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
di: Selena Z. Kuo, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
di: Ao Gao, et al.
Pubblicazione: (2026)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
di: Huiying Lin, et al.
Pubblicazione: (2025)

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis
di: Nadir Abbas, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
di: Bo Li, et al.
Pubblicazione: (2024)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
di: Yi Pei, et al.
Pubblicazione: (2025)

Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study
di: Kris V. Kowdley, et al.
Pubblicazione: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
di: Conrado Fernandez‐Rodriguez, et al.
Pubblicazione: (2024)

Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial
di: Cynthia Levy, et al.
Pubblicazione: (2026)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
di: Aisha Alawi, et al.
Pubblicazione: (2025)

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi‐Centre Propensity Score Matched Analysis
di: Saqr Alsakarneh, et al.
Pubblicazione: (2025)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
di: Pardhu Bharath Neelam, et al.
Pubblicazione: (2025)

Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU
di: María José Casanova, et al.
Pubblicazione: (2025)

Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis
di: Wei‐Zhen Tang, et al.
Pubblicazione: (2024)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
di: Matthias Kelm, et al.
Pubblicazione: (2025)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)
di: Marco Sanduzzi‐Zamparelli, et al.
Pubblicazione: (2026)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
di: Soon Sun Kim, et al.
Pubblicazione: (2025)

The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease
di: Sebastiaan ten Bokkel Huinink, et al.
Pubblicazione: (2025)

Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
di: Yi Xiang, et al.
Pubblicazione: (2025)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
di: Nathan Grellier, et al.
Pubblicazione: (2025)

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss
di: Simon J. Hume, et al.
Pubblicazione: (2025)

Cohort Study: Long‐Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients
di: Mohamed H. Eldesouki, et al.
Pubblicazione: (2026)

Intestinal Ultrasound Transmural Healing Was Associated With Improved Long‐Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study
di: Clara Yzet, et al.
Pubblicazione: (2025)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
di: Shlomi Cohen, et al.
Pubblicazione: (2025)

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
di: Silvio Danese, et al.
Pubblicazione: (2025)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
di: Silvia Nardelli, et al.
Pubblicazione: (2025)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
di: Austin Haynesworth, et al.
Pubblicazione: (2024)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
di: Xingfei Pan, et al.
Pubblicazione: (2025)

Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
di: Aakash Desai, et al.
Pubblicazione: (2025)

Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study
di: Chachrit Khunsriraksakul, et al.
Pubblicazione: (2025)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
di: Mathilde Osty, et al.
Pubblicazione: (2025)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
di: Muhammad Ibrahim Khalil, et al.
Pubblicazione: (2025)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
di: You‐Jian Xu, et al.
Pubblicazione: (2024)

Underdiagnosis of Alpha‐1 Antitrypsin Deficiency in Cirrhotic Liver Transplant Candidates: Findings From a Multicenter Retrospective Study
di: Manon Evain, et al.
Pubblicazione: (2025)